Business Context and Reporting Period
Company: Bioaffinity Technologies, Inc. (BIAF)
Filing Type: Form 8-K (Current Report)
Date of Report: July 22, 2026
Reporting Period: Specific event date of July 22, 2026
Business Overview: The Company is a Delaware corporation focused on developing diagnostic tests. It is classified as an emerging growth company and trades on the Nasdaq Capital Market.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on a corporate event rather than financial performance data.
Material Changes
Strategic Collaboration: On July 22, 2026, the Company announced a collaboration with Pictor, Inc., a targeted proteomic platform company.
Objective: The partnership aims to support the development and commercialization of the Company's next-generation diagnostic tests.
Target Application: The tests are designed to provide a more complete picture of lung inflammation in patients with asthma and chronic obstructive pulmonary disease (COPD).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the collaboration but does not include specific financial guidance, quantitative outlook, or detailed risk factors within the body of this 8-K.
Unusual Items: None reported beyond the strategic partnership announcement.
Investor Verification Checklist
- Review the full text of the press release attached as Exhibit 99.1 for specific terms of the collaboration with Pictor, Inc.
- Verify the commercial timeline and milestones associated with the new diagnostic tests for asthma and COPD.
- Check subsequent filings for any financial impact or revenue recognition related to this partnership.
- Confirm the Company's status as an emerging growth company and any associated reporting exemptions.